08:00 , Dec 15, 2008 |  BC Week In Review  |  Clinical News

Visicol regulatory update

FDA said in an alert that it would require Salix to add boxed warnings to its OsmoPrep and Visicol bowel cleansing agents to warn of the risk of acute kidney injury. FDA also will require...
08:00 , Dec 15, 2008 |  BioCentury  |  Finance

Ebb & Flow

In good economic times, companies that run into problems can often avoid tough decisions - such as dropping programs or employees, or shutting their doors - by raising money from less savvy investors. Meanwhile, disgruntled...
01:57 , Dec 12, 2008 |  BC Extra  |  Company News

Salix's OsmoPrep, Visicol to get boxed warnings

Salix (NASDAQ:SLXP) fell $1.17 (14%) to $7.44 on Thursday after FDA said it would require the company to add boxed warnings to oral sodium phosphate products OsmoPrep and Visicol to warn of the risk of...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Mayoly-Spindler S.A.S., Salix sales and marketing update

SLXP granted Mayoly-Spindler exclusive rights to market OsmoPrep in France to cleanse the bowl. SLXP is eligible to receive up to $1 million in milestones, plus royalties. Mayoly-Spindler expects French marketing approval in 1H09. The...
07:00 , Apr 23, 2007 |  BC Week In Review  |  Company News

Dr. Falk Pharma, Salix sales and marketing update

SLXP granted Falk exclusive rights to market Diacol sodium phosphate 1,500 mg tablets in certain countires in Europe to cleanse the colon as a preparation for colonoscopy. The rights exclude France and Italy, where Falk...
08:00 , Dec 18, 2006 |  BC Week In Review  |  Clinical News

Diacol regulatory update

The U.K.'s MHRA granted marketing approval for 1,500 mg tablets of Diacol to cleanse the colon as a preparation for colonoscopy. The second-generation sodium phosphate purgative is marketed under the name OsmoPrep in the U.S....
07:00 , May 29, 2006 |  BC Week In Review  |  Clinical News

OsmoPrep: Post-marketing study updated data

Pooled data from Phase II and Phase III trials comparing Osmoprep to Visicol showed that the percentage of ascending colon cleansing (ACC) responders was significantly higher for both the 40 tablet (96%) and 32 tablet...
07:00 , Apr 24, 2006 |  BC Week In Review  |  Clinical News

OsmoPrep gastrointestinal data

Data from a single-blind study in 411 patients completing a scheduled colonoscopy showed that a significantly greater percentage of patients who used OsmoPrep tablets recorded a mean overall colon cleansing score of 'excellent' compared to...
08:00 , Mar 20, 2006 |  BC Week In Review  |  Clinical News

OsmoPrep regulatory update

FDA approved an NDA for OsmoPrep to cleanse the bowel prior to colonoscopy. The second-generation sodium phosphate purgative was received through the 2005 acquisition of InKine Pharmaceutical. SLXP also markets Visicol , a first-generation purgative,...
02:37 , Mar 18, 2006 |  BC Extra  |  Company News

FDA approves Salix's OsmoPrep

FDA approved OsmoPrep sodium phosphate tablets from Salix (SLXP) to cleanse the bowel prior to colonoscopy. SLXP gained the second-generation sodium phosphate purgative (formerly INKP-102 ) through its acquisition of InKine last year. SLXP also...